AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02018094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: 500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
Study NCT01377259 — intervention group
Intervention type: OTHER
Intervention: tissue oxygen saturation, spinal anesthesia
Description: regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia
Study NCT02806869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose of ibuprofen (800 mg tablet)
Study NCT02806869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pulmocare, two 8.0 oz (236.6 mL) cans
Study NCT01097343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel 75 mg
Description: 75 mg once daily
Study NCT01097343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 150 mg
Description: clopidogrel 150 mg
Study NCT03253913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Patients will have been on a stable dose of sirolimus prior to enrolling and will continue that throughout the study.
Study NCT03253913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Escalating doses of resveratrol will be given throughout the study. Patients will start at 250mg daily for 8 weeks, followed by 500mg daily for 8 weeks, and 500mg BID for the last 8 weeks.
Study NCT01321606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001
Description: Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10\^10 organisms
Study NCT01321606 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill (placebo)
Description: Placebo identical to the active product will be given
Study NCT02053363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid (Cyklokapron)
Study NCT02053363 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid (Cyklokapron)
Study NCT02200159 — intervention group
Intervention type: DRUG
Intervention: Sedation with dexmedetomidine
Study NCT03731312 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is an observational study and no interventions will be administered.
Study NCT02785380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery(LS)
Description: For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
Study NCT02785380 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RFA
Description: RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
Study NCT02539212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: microwave ablation
Description: ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
Study NCT02539212 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: radiofrequency ablation
Description: ultrasound-guided radiofrequency ablation is performed to treat hepatocellular carcinoma patients
Study NCT05116839 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: the first 15 minutes with pressure support ventilation
Description: PSV pressure support ventilation:triggered by minute volume \< 3 Liter ,with no frequency
Study NCT05116839 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: the following 15 minutes ventilation will be changed to continous positive air way pressureCPAP mode
Description: continous positive air way pressure CPAP mode at 10 cm H2o .
Study NCT05116839 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: i gel air way
Description: supraglottic air way device
Study NCT05116839 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: i gel air way
Description: supraglottic air way device
Study NCT04628715 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RSA biofeedback
Description: Biofeedback intervention based on breathing at resonance frequency
Study NCT04628715 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: RSA biofeedback
Description: Biofeedback intervention based on breathing at resonance frequency
Study NCT03812978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart phone application
Description: Smart phone application including exercise videos, push notifications for exercise, questions and answers, exercise diary.
Study NCT03630939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESR-114
Description: ESR-114 Topical Gel
Study NCT03630939 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Topical Gel
Study NCT01622075 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SeQuent® Please
Description: SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
Study NCT01622075 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Liberte
Description: Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
Study NCT03951207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuampin 10/5mg
Description: Rosuvastatin 10mg/Amlodipine 5mg qd for 8 weeks
Study NCT03951207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuampin 20/5mg
Description: Rosuampin 20/5mg qd for 8 weeks
Study NCT03951207 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine/Atorvastatin 5/20mg
Description: Amlodipine/Atorvastatin 5/20mg qd for 8 weeks
Study NCT03900637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprorelin acetate
Description: In premenopausal women, 3.75mg of leuprorelin acetate is subcutaneously administered once every 4 weeks for 16 weeks. (if needed, maximum for 24 weeks)
Study NCT03900637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 2.5 mg tablet is orally administered once a day, without regard to meals, for 16 weeks (if needed, maximum for 24 weeks)
Study NCT03900637 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: MammaPrint
Description: In this study, patients with MammaPrint test is performed, neoadjuvant chemotherapy is conducted to genomic High Risk patients, and neoadjuvant endocrine therapy is conducted to Low Risk patients.
Study NCT03907098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostar
Description: an anti-angiogenesis drug
Study NCT03907098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Physician's choice
Study NCT01263730 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tai Chi
Description: Tai Chi training consists of a sequence of slow, soft, and graceful movements derived from the martial arts. It is considered as a moving form of yoga and meditation combined. Tai Chi has been considered as one form of oriental healing arts, like acupuncture, which fosters the circulation of this 'chi' or energy within the body.
Study NCT00761436 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Spheramine (BAY86-5280)
Description: Stereotactic Intrastriatal Implantation
Study NCT02052375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP2408
Description: subcutaneous injection
Study NCT02052375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: subcutaneous injection
Study NCT02935634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT02935634 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ipilimumab
Description: Specified dose on specified days
Study NCT02935634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relatlimab
Description: Specified dose on specified days
Study NCT02935634 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986205
Description: Specified dose on specified days
Study NCT02935634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: Specified dose on specified days
Study NCT02310802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE001 dose 1
Description: OBE001 dispersible tablets for single oral administration
Study NCT02310802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE001 dose 2
Description: OBE001 dispersible tablets for single oral administration
Study NCT02310802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OBE001 dose 3
Description: OBE001 dispersible tablets for single oral administration
Study NCT02310802 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dispersible tablets for single oral administration
Study NCT02730845 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intra-articular dexmedetomidine
Description: Patients will receive an intra-articular mixture of 19 ml bupivacaine 0.5% with epinephrine 1:200.000 added to 1ml (1 µg/kg) of dexmedetomidine (total volume 20 ml), and i.v. saline 20 ml infused over 10 min starting with local anesthesia
Study NCT02730845 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous dexmedetomidine
Description: Patients will be injected intra-articularly with mixture of 19 ml 0.5% bupivacaine with epinephrine 1:200.000 and 1 ml of isotonic saline (total volume 20 ml), in addition to i.v. 20 ml saline containing 1 µg/kg dexmedetomidine over 10 min infusion starting with local anesthesia.
Study NCT01419275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon contrast agent
Study NCT02018094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine
Description: Alcoholic Chlorhexidine skin pre-op preparation
Study NCT01419275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Arterial spin label sequence for the purpose of measuring collateral flow
Study NCT02486510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.~Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours
Study NCT02018094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teicoplanin
Description: Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
Study NCT04688346 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HemeRX epinephrine pellets
Description: Racemic Epinephrine Pellet
Study NCT04688346 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HemeRX epinephrine pellets
Description: Racemic Epinephrine Pellet
Study NCT03524833 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Metronidazole
Description: Twenty patients receive intraluminal Metronidazole eradication of H. pylori.
Study NCT03524833 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lansoprazole, Amoxicillin, Metronidazole
Description: Patients fail to achieve intraluminal eradication of H. pylori will be assigned to the oral antibiotic triple therapy which contains Lansoprazole, Amoxicillin and Metronidazole for 14 days.
Study NCT02074579 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TU-100
Description: 15g daily, orally as 5g three times daily for 4 consecutive weeks
Study NCT02074579 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo given 5g three times daily orally for 4 consecutive weeks
Study NCT01542359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yogic practice
Description: breathing, meditation, physical postures
Study NCT01542359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Exercise
Description: Standard physical exercises such as toe touch in standing, curl ups, push ups, leg lifts
Study NCT00597935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SSLF
Description: sacrospinous ligament fixation (SSLF)
Study NCT00597935 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ULS
Description: uterosacral vaginal vault ligament suspension (ULS)
Study NCT00597935 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PMT
Description: Pelvic muscle training and exercises (PMT)
Study NCT04224493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Stage 2:~Placebo administered orally twice daily in continuous 28-day cycles. Placebo will be administered as monotherapy twice daily dose for up to 2 years after the initial 12 months of combination therapy.
Study NCT04224493 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide 20 mg capsules or 10 mg capsules (if creatinine clearance ≥60 mL/minute or \<60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.
Study NCT01163162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: 2 mcg oral Paricalcitol once per day for 7 days
Study NCT00563836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Catumaxomab
Description: 10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
Study NCT03005977 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Urodynamics
Description: UDS is to be performed with prolapse reduced by a speculum. The patient will be asked to valsalva three times then cough while seated after 150 ml of fluid is instilled in the bladder and then again at 300 ml. The same provocative measures will be performed at capacity, with the catheter in place and without the catheter if no leak is identified. If the patient leaks at any volume or if the patient leaks during the cough pressure profile (CPP), the test will be considered positive. If the patient does not leak during filling nor during the CPP then the test will be considered negative.
Study NCT04224493 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 20 mg capsules or 10 mg capsules (if creatinine clearance ≥60 mL/minute or \<60 mL/minute), administered PO QD on days 1 to 21 for 12 cycles.
Study NCT01160055 — intervention group
Intervention type: PROCEDURE
Intervention: Middle ear fluid and urine.
Description: Middle ear fluid and urine collection.
Study NCT03218254 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Methylphenidate
Description: Titration of MTP for treatment of fatigue
Study NCT03218254 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Placebo
Study NCT00121303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Study NCT00121303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cytarabine
Study NCT00121303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride
Study NCT04224493 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
Study NCT04224493 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on days 1, 8, 15, and 22 of cycle 1; then on day 1 of cycles 2 to 5.
Study NCT03766568 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JGG endoscope(R)
Description: The JGG endoscope(R) is attached to the new generation of Heine® otoscopes with a LED light source that allows the inspection of the ostium in the middle meatus and collection of material for bacterial culture for the diagnosis of ABRS in primary care. After local anaesthesiology of the cavum nasi a sample material for cultures can be gained (earliest 10 min after local anaesthesia). The diagnostic procedure poses patients at minimal risk for complications and is of very little and short-termed discomfort.
Study NCT00121303 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: daunorubicin hydrochloride
Study NCT00121303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemtuzumab ozogamicin
Study NCT01205620 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ITPR
Description: • Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
Study NCT01205620 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: No intervention
Description: No intervention will be performed in the control group
Study NCT04892290 — intervention group
Intervention type: OTHER
Intervention: Conservative Treatment for Postdural Puncture Headache
Description: The patients in Group C were given continuous bed rest in the supine position, 3000 mL daily hydration, 6 mg kg-1 aminophylline , 2 g day-1 paracetamol and 65 mg day-1 caffeine as conservative treatment. Topical SGB was applied to patients in Group SGB in addition to conservative treatment.
Study NCT03862690 — intervention group
Intervention type: DRUG
Intervention: BIAsp 30
Description: Participants will receive commercially available BIAsp 30 once daily (QD), twice daily (BID) or thrice daily (TID) for 24 weeks according to routine clinical practice. The physician will determine the starting dose and any potential later change to the dose. The decision to switch the patient to NovoMix® 30 is at the treating physician's discretion and independent from the decision to include the patient in the study.
Study NCT00967512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cenersen
Description: solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
Study NCT00967512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
Study NCT00967512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: idarubicin, cytarabine
Description: idarubicin, cytarabine
Study NCT03644940 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CustomSight
Description: Subpopulation-specific clinical decision support (CDS) system for severe sepsis detection
Study NCT00967512 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: idarubicin, cytarabine
Description: idarubicin, cytarabine
Study NCT03665298 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Application
Description: App that helps patients find syringe exchange programs, safe way to dispose of needles, access to naloxone kits and access to free medical care and addiction treatment programs.
Study NCT02866435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: In each clamp, a small intravenous catheter is placed in participant's arm for infusion of insulin together with potassium phosphate and glucose. Insulin is a hormone that body makes naturally and it causes blood sugar to decrease. Insulin (and glucose) will be infused in calculated doses to maintain blood sugar level in the target range of 95 mg/dl or 50 mg/dl depending on the clamp.
Study NCT02787993 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Mult-Symptom management(CBT)
Description: Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
Study NCT02892461 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical cord milking
Description: As same as that in arm descriptions.
Study NCT01778088 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: I-131-CLR1404 Injection
Study NCT04349306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RASBURICASE SR29142
Description: Pharmaceutical form:solution for infusion Route of administration: intravenous
Study NCT02018094 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
Study NCT01532063 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: INTUBATION IN INTENSIVE CARE UNIT
Description: Standard intubation procedure used in Intensive Care Unit